4D Molecular Therapeutics, Inc. (FDMT) Total Assets by Year
4D Molecular Therapeutics, Inc. closed fiscal year 2025 with $566.7M in total assets, $61.0M in total liabilities and $505.7M in shareholder equity. This represents an increase of 1.1% from the prior fiscal year. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters 4D Molecular Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
FDMT Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K |
|---|---|---|---|---|---|---|---|
| Total Assets | $566.7M+1.1% | $560.4M+64.9% | $339.9M+29.8% | $261.8M-25.9% | $353.5M+22.6% | $288.3M+395.1% | $58.2M |
| Total Liabilities | $61.0M+22.6% | $49.8M+55.3% | $32.1M+5.1% | $30.5M-11.3% | $34.4M+7.6% | $31.9M-75.7% | $131.2M |
| Total Equity | $505.7M-1.0% | $510.6M+65.9% | $307.8M+33.1% | $231.3M-27.5% | $319.1M+24.5% | $256.4M+451.4% | -$73.0M |
FDMT Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $492.6M+4.0% | $512.9M-0.5% | $566.7M-99.9% | $424.0M-29.8% | $473.6M-23.6% | $515.7M-18.1% | $560.4B+164771.7% | $604.0M+67.0% | $620.1M+75.9% | $629.9M+158.1% | $339.9M+29.8% | $361.6M+29.1% |
| Total Liabilities | $85.0M+61.1% | $61.1M+32.7% | $61.0M-99.9% | $55.0M+7.7% | $52.7M+66.0% | $46.0M+56.9% | $49.8B+155155.4% | $51.1M+61.2% | $31.8M+16.1% | $29.3M+15.4% | $32.1M+5.1% | $31.7M+10.3% |
| Total Equity | $407.7M-3.1% | $451.8M-3.8% | $505.7M-99.9% | $369.0M-33.3% | $420.9M-28.5% | $469.7M-21.8% | $510.6B+165773.3% | $552.9M+67.6% | $588.3M+80.9% | $600.6M+174.7% | $307.8M+33.1% | $329.9M+31.2% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More 4D Molecular Therapeutics, Inc. financials
Frequently Asked Questions
What was 4D Molecular Therapeutics, Inc.'s total assets in fiscal year 2025?
4D Molecular Therapeutics, Inc. closed fiscal year 2025 with $566.7M in total assets, $61.0M in total liabilities and $505.7M in shareholder equity.
How fast is 4D Molecular Therapeutics, Inc.'s total assets growing?
4D Molecular Therapeutics, Inc. (FDMT) total assets rose by 1.1% year over year, from $560.4M to $566.7M in fiscal year 2025.
How has 4D Molecular Therapeutics, Inc.'s total assets changed over the years?
Across the 7 fiscal years this page covers, 4D Molecular Therapeutics, Inc. (FDMT) total assets went from $58.2M in fiscal year 2019 to $566.7M in fiscal year 2025.
What was 4D Molecular Therapeutics, Inc.'s total assets in the most recent quarter?
4D Molecular Therapeutics, Inc. (FDMT) reported $492.6M in total assets in Q2 2026. This represents an increase of 4.0% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what 4D Molecular Therapeutics, Inc. (FDMT) reported on that line in every period on record.